Incubator Company Profiles
AccelBio provides results for biotechnology applications and pharmaceutical outcomes with a focus on customized neurobiology discovery research. With AccelBio's expertise in molecular cell biology and animal work, it leverages premier bioassays in multiple formats, including high-throughput screens using chemically unique entities for drug discovery, and exclusive use of superior primary cells through Evergreen Biosciences. AccelBio's contract services enable the highest quality R&D focused on genetic models and disease pathways.
Contact: Jason Dictenberg, Ph.D., CEO (718-845-7374)
Aircela Inc. is a climate tech startup developing an appliance-sized unit to turn CO2 from the air into carbon-neutral gasoline. Aircela's ultra-small-scale technology allows customers as small as individual households to make their own fuel, replacing fossil hydrocarbons one vehicle at a time.
Applied Biological Laboratories Inc. is a biotechnology company committed to research, development, manufacturing and distribution of scientifically validated natural products.
BioMolecular, Inc. is a leading technology, product and service provider for the life science community. The company has developed a variety of biological research reagents, such as ultra-speed clone vector, ultra-sensitive PCR system, one step Western blot and magic protein sample solution. These reagents are widely used in molecular biological research, drug discovery and clinical diagnosis. The company’s research services include customer gene expression, DNA and RNA purification, gDNA and cDNA library construction, PCR and gene clone, RT-PCR, clinical assay, primer and gene synthesis, DNA sequencing and contracting research project.
Contact: Gang Wu (917-362-0788) - email@example.com
ChemFinity Technologies, Inc. is developing highly selective adsorbent and membrane materials that exhibit exceptional performances for molecular separations spanning across the periodic table. ChemFinity is focused on separations that would help alleviate environmental injustice issues, with applications in precious metal recovery, water desalination, and gas separations.
CMP Scientific Corp. currently develops, manufactures, and sells nanoLC capillary columns and CE-ESI-MS ion sources. CMP Scientific is founded by experts in the analytical science field, especially the LC-MS and CE-MS coupling technologies. It seeks to become an industry leader as an analytical instrumentation company with five core products/services: nanoLC capillary columns, CE-ESI-MS ion sources, CE instruments, CE consumables, and CE-ESI-MS CRO service.
Contact: James (Qiangwei) Xia, Ph.D., CEO & Principal Scientist (718-360-7803)
Concarlo Holdings, LLC (Concarlo) is a start-up drug development company focused on
innovative therapeutics and diagnostics for unmet needs in oncology.
Contact: LisaMarie Casey - Info@concarlo.com
DrinkSavvy, Inc. is developing colorimetric chemical sensors that detect analytes, such as drugs, pathogens, bacteria, and explosives, for real-time detection in field use, without the need for secondary analysis using lab equipment or spectrometry. The chemical sensors will be embedded in plastic stirrers, straws and cups and provide a colorimetric signal to the consumer in order to prevent consumption of illicit drugs and ensuing drug-facilitated sexual assault and crime.
Contact: Brendan Walker
EpiBone, Inc. is a revolutionary bone reconstruction company that allows patients to grow their own bone. The company's pioneering technology utilizes a scan of the patient's bone defect and the patient's own stem cells to construct and cultivate a defect-specific autologous-like bone graft. EpiBone is strategically positioned to provide a superior bone graft that will provide exact defect repair, a simplified surgical procedure, improved bone formation and regeneration, and shorter recovery times without the complications of foreign body implantation, to the over 900,000 patients who undergo bone-related surgeries each year.
Epi One is a start up biotechnology company that aims to develop tests for the clinical diagnosis of diseases.
Tel: (718) 676-0696
The need for an alternative to one’s own tissue for wound healing and repair has existed as long as reconstructive surgery itself. Fesarius Therapeutics is an early stage company that will develop and manufacture engineered skin and tissue replacement products using patented microsphere hydrogel technology invented by Dr. Jason Spector at the Weill Cornell Medical College Laboratory for Bioregenerative Medicine & Surgery.
Contact: Brett Spector, CEO – firstname.lastname@example.org
First Wave BioPharma, Inc. is a biotechnology company that develops non-systemic recombinant protein therapies for the treatment of gastrointestinal (GI) and infectious diseases. First Wave's two leading therapeutics are: MS1819 Lipase (Phase IIa) for the treatment of severe malnutrition associated with Chronic Pancreatitis and Cystic Fibrosis; and AZX1101 (preclinical) which reduces the incidence of Clostridium difficile infection, one of the most common hospital acquired infections.
HistoWiz, Inc. is a histopathology service company that processes, embeds, cuts, stains mouse tissue specimens and digitalizes the results for cancer researchers in academia and pharma. Unlike academic core facilities and CROs, HistoWiz guarantees a 3 day turn-around time and provides global access to whole-slide digital results, online collaboration features, low-cost digital data management, a cancer image database, and mouse cancer pathology expertise. The company's mission is to fight cancer cooperatively instead of individually by connecting scientists and doctors for online collaboration.
Contact: Ke Cheng (212-722-1456)
IAVI's Vaccine Design and Development Laboratory (DDL) is a versatile facility designed to create novel immunogens, develop viral vectors, evaluate potency and advance promising candidates to clinical evaluation. The DDL has also established common preclinical standards for the vaccine field. Their goals are to understand the basis of naturally evoked, broadly neutralizing antibodies against HIV and other Emerging Infectious Diseases (EID) such as, but not limited to, Lassa fever, Marburg virus, and Covid-19.
Kinnos Inc. aims to raise the standard of infectious disease decontamination to protect healthcare workers, patients, and the general public. The company's first product, Highlight, is a point-of-use additive for existing disinfectants that eliminates human error and greatly increases visibility, coverage, and end-user compliance.
Lucerna, Inc. is a RNA-based research tool company that uses a fluorescent aptamer platform for the purpose of: 1.) Developing metabolite sensors for therapeutic diagnostics, 2.) Developing fluorescent assays against hard-to-access targets to enable high-throughput drug discovery, and 3.) Providing plug-and-play RNA imaging systems as research reagents.
Lumidyne Technologies specializes in the development and manufacturing of advanced fluorescent probes that enable a broad range of structural and cell biological imaging applications.
Mirimus is a high-tech business with the expertise in RNAi technologies required for development of superior tools for potent gene silencing, both in cells and animal models. Its advanced RNAi technologies are critical for the generation of animal models that can pave the way drugs are developed by pin-pointing potential toxicities and preventing harmful side-effects of therapeutics in patients. Mirimus is also engaged in the design, development and pioneering of new CRISPR/Cas9 genome editing technologies to develop advanced human disease models that are crucial for the preclinical evaluation of new therapeutics.
New York Huaqi Bioengineering, LLC develops new products in modification or growth of liver organ in vitro to meet the shortage of liver organs in clinic.
Contact: Lili Xu, Founder & CEO (914-316-0801)
Paritic, Inc. provides 3D medical imaging navigation system for minimally invasive surgery. Paritic specializes in medical imaging software and hardware systems for clinical usage. Paritic offers intra-operative navigation system, as well as 3D imaging software products and services for surgical planning, surgical training, virtual surgery post-operative evaluation. With Paritic’s technology, surgery is becoming more secure, more accurate and more effective.
Contact: Yale Ji (212-901-8608) - email@example.com
Psomagen Corp., previously named Macrogen Corp. in the U.S., has been the corporate partner of choice on genomic sequencing for many academic and commercial organizations. The company's superior quality, cost effective business model and customer focused services allowed it to expand and grow into an international organization. Psomagen's sequencing experience uniquely positions it to contribute in both the Sanger and the next generation genomic sequencing.
Relavo, Inc. is a medical device that aims to reduce infection risk associated with catheters and home therapies. Relavo's initial focus is on changing the way that kidney failure patients receive treatment by making home dialysis safer and more accessible. The company's first product, the PeritoneX, is a connection device that disinfects peritoneal dialysis (PD) tubes to reduce infection risk and enable PD patients to receive safe, quality care at home.
Vasocure is a clinical-stage vascular therapeutics company with the world’s first peptide to directly treat neointimal disease and atherosclerosis.
Werewool is a biotechnology company developing protein-based, biodegradable textile fibers with inherent, DNA-programmed color and performance. Driven by the principles of biomimicry, Werwool fibers are inspired by how nature builds color and function into materials, to create low impact, compostable, textile fibers with vibrant structural color and performance properties like strength, stretch and moisture management achieved through protein engineering. Werewool fibers are engineered to offer the textile industry performance properties and aesthetics without the high environmental cost of conventional synthetic fibers and dyes.
Xylyx Bio is revolutionizing the $7B+ cell culture market with its first-in-class tissue-specific biomaterials, enabling faster, more accurate and actionable results for scientists working in pharmaceutical development, cell biology research and regenerative medicine. Rather than isolated components or synthetic materials, the Company’s innovative product platform provides a natural, physiological cell culture environment in which to develop, test and deliver treatments and cures to patients more quickly and less expensively.